Defining acquisition cost when your buyer is a hospital committee

Nobody buys a Stryker Mako. A surgeon asks for one. What follows is a capital request, a value analysis committee (VAC) review of the clinical evidence, a finance model of implant pull-through, a sterile processing sign-off, and, in a multi-hospital system, a second review at network level. Eighteen months can pass between the first congress conversation and the first case. Along the way your budget paid to influence a dozen people, none of whom signs anything, and any one of whom can end it.

So what did that account cost to acquire? A consumer formula answers fast and lands wide of the mark, because it assumes one buyer, one decision and one quarter.

Why standard CACCACCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.View full definition → breaks in medtech

Customer acquisition cost (CAC) is the total sales and marketing spend needed to win one new customer over a defined period, divided by the number of customers won.

$$CAC = \frac{\text{Sales spend} + \text{Marketing spend}}{\text{New customers acquired}}$$

Three features of the committee sale break that arithmetic:

• Multiple buyers, one sale. Clinicians want it, procurement questions the price, the VAC weighs evidence against budget, and infection control can veto on reprocessing grounds. One no is enough.
• Long cycles. Capital equipment commonly runs 12 to 24 months, so spend and revenue land in different fiscal years.
• Blended channels. Field reps, medical science liaisons (MSLs, scientists who discuss clinical data with physicians), congresses and health economics content all touch the same account.

Hold on to the counter-example. Butterfly Network sells a handheld whole-body ultrasound probe at a list price in the low thousands of dollars with a required software subscription, cheap enough for a department head to buy without convening anyone. The same company also sells enterprise deployments to health systems, and those go through full value analysis. Two buying units, two cycles, two CACs. A company-wide average across both describes neither, and it hides the fact that the enterprise motion can cost tens of times more per account than the self-serve one.

Building a fully loaded CAC

Define the cohort window to match the sales cycle, not the fiscal quarter. If the average cycle is 18 months, measure spend across an 18-month window aligned to when those deals started.

Include these buckets:

1. Field sales: salaries, commissions, travel, demo and loaner fleet depreciation, clinical specialists supporting evaluations.
2. Marketing: congress booths, symposia, KOL (key opinion leader) engagement, reprints, webinars, digital.
3. Health economics and outcomes research (HEOR) built specifically to clear the VAC. In medtech this is acquisition spend, not R&D.
4. Sales enablement: ROIROIReturn on Investment: the ratio of net profit to the cost of an investment. A 300% ROI means each dollar invested returns $3.View full definition → calculators, budget impact models, the evidence dossiers reps carry into committee.

Exclude manufacturing, ongoing service and post-sale clinical training, which belong to cost to serve.

One definition does more damage than any of these buckets if you get it wrong: what counts as an acquisition. VAC approval is not a sale. A device can sit on the approved catalogue and never be ordered, because listing grants permission and the surgeon still has to change habit. Count the first commercial order, or the first clinical case for capital, and treat approval as a stage. Teams that book approvals as wins flatter CAC and then cannot explain why revenue trails the win count by two quarters. Settle the unit of account too: an IDN contract covering twelve hospitals is one negotiation and twelve sites of use. Either convention works; switching mid-year makes the trend line meaningless.

A worked example

A mid-size orthopedic implant company selling into US hospitals. Over an 18-month cohort:

New hospital accounts won in the cohort: 40.

$$CAC = \frac{6{,}000{,}000}{40} = \$150{,}000 \text{ per hospital account}$$

What that $150,000 is actually made of

Every dollar spent on the committees that said no sits in the numerator; only the winners sit in the denominator. CAC is a win-rate metric in disguise. Hold the $6m flat and move wins from 40 to 25 and CAC becomes $240,000, a 60 percent jump with no change in spend and no campaign performing worse. Before cutting a program, establish whether the drift came from spending more or converting less. The two fixes point in opposite directions.

Read the result against the multi-stream account value the lifetime valuelifetime valueLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → lesson builds, over a decade rather than a year, and leave the question of which ratio is normal for your segment to the benchmarks lesson. For the underlying mechanics, the Corporate Finance Institute CAC primer is a solid free reference.

A quieter distortion: in orthopedics and imaging the capital unit is often placed rather than sold, with the hospital committing to implant or consumable volume instead of paying up front. That placement lands on your balance sheet as equipment and depreciates through cost of goods, never touching the sales and marketing line. Reported CAC falls while the real cost of winning the account rises. If the placed fleet is growing faster than revenue, your CAC number is fiction; push the annual depreciation of placed units into the acquisition cohort, or accept that a placement-heavy region cannot be compared with a purchase-heavy one.

Segment CAC by buyer touchpoint

A blended CAC hides where money is wasted. Break the spend down by committee stakeholder and ask which touch moves deals.

• Clinician CAC: KOL programs, congress education, rep clinical support per won account.
• Procurement CAC: pricing tools, contract support, GPO (group purchasing organization, a body that negotiates prices for many hospitals at once) engagement.
• VAC CAC: HEOR dossiers and economic evidence.

GPOs such as Vizient and Premier gatekeep a large share of US hospital purchasing, so a deal stalls even after surgeons say yes. High clinician enthusiasm plus stalled VAC approval means HEOR is underfunded relative to KOL spend. That is an allocation problem only segmentationsegmentationDividing a market into distinct groups of customers who share similar needs, characteristics or behaviours, so each group can be served with a tailored approach.View full definition → exposes.

🎬 [VIDEO: "How Hospitals Actually Buy Medical Devices" - youtube.com - an overview of value analysis committees and the medtech purchasing chain]

US vs Europe: what changes

The buying unit shifts across markets, and so does where acquisition dollars go.

• United States: purchasing dominated by IDNs (integrated delivery networks, large multi-hospital systems) and GPOs. Spend skews toward economic evidence and contracting.
• Europe: centralized or national tenders in many countries. In England, NHS Supply Chain aggregates procurement, and HTA bodies such as NICE act as an evidence gate. Winning means qualifying for a tender rather than persuading a local committee, so spend skews toward regulatory dossiers, health technology assessment evidence and bid response capacity.

Mindray built much of its European and emerging-market monitoring and ultrasound position through exactly this route, competing on total cost of ownership inside public tenders. Tender CAC behaves differently in one important way: it is binary and lumpy. Lose the framework and the entire bid cost writes off against zero accounts, so quarterly CAC is undefined. Win a national framework and cost per site can drop by an order of magnitude in a single period. Read tender-market CAC over multi-year windows only. And because frameworks re-tender every few years, a share of what your team calls retention spend is re-acquisition against the same committee.

AttributionAttributionA framework for assigning credit to the touchpoints that contributed to a conversion, so you can measure which channels and interactions actually drive results.View full definition → over an 18-month cycle

A congress touch in month 2 may enable a VAC win in month 16. Two workable approaches:

• Multi-touch attributionMulti-touch attributionA method that distributes conversion credit across all marketing touchpoints in the customer journey, rather than crediting only the first or last interaction.View full definition →: credit every touchpoint in a won deal's history. Requires CRMCRMCustomer Relationship Management: software and strategy to manage and analyse customer interactions throughout their lifecycle.View full definition → logging that actually happens.
• Cohort-based CAC: divide total cohort spend by accounts won, as above. Cruder, and far harder to break.

Start with cohorts, because CRM hygiene across an 18-month multi-stakeholder account is usually poor. A minimal query:

SELECT
  cohort_start_quarter,
  SUM(sales_and_marketing_spend) AS total_spend,
  COUNT(DISTINCT won_account_id)  AS accounts_won,
  SUM(sales_and_marketing_spend) / COUNT(DISTINCT won_account_id) AS cac
FROM deal_cohorts
WHERE deal_start_date BETWEEN '2024-07-01' AND '2025-12-31'
GROUP BY cohort_start_quarter;

Align the spend window to deal_start_date, not close date, so you are not charging this quarter's spend against last year's wins.

Payback period: the cash reality of long cycles

CAC payback is how long the account's gross profit takes to repay its acquisition cost.

$$\text{Payback (months)} = \frac{CAC}{\text{Monthly gross profit per account}}$$

Take an account throwing off roughly $120,000 in annual gross profit, the sort of figure the lifetime value lesson builds properly across capital, implants and service. Monthly gross profit is $10,000.

$$\text{Payback} = \frac{150{,}000}{10{,}000} = 15 \text{ months}$$

Add the 18-month cycle and you are about 33 months from first touch to breakeven. That is normal in capital medtech, and it is why defunding HEOR in month 10 to rescue a quarter destroys deals you already paid two thirds of the cost to start. The second-order effect is worse than the lost revenue: the committee that reviewed an incomplete dossier will remember it at the next review cycle, and re-entry costs more than entry.

Common ways teams get CAC wrong

• Counting only close-quarter spend. Understates CAC badly in long cycles.
• Booking VAC approval as a win. Permission is not an order.
• Ignoring HEOR as a marketing cost. Committee evidence is acquisition spend.
• Blending distinct buying units, whether self-serve and enterprise inside one company or tender and committee markets.
• Forgetting the fleet. Loaner, evaluation and placed units tie up capital and belong in a fully loaded number.

Key Takeaways

• Match the measurement window to the sales cycle. For an 18-month deal, compute CAC across an 18-month cohort aligned to deal start.
• Fix the acquisition event before the formula. First order or first case, never committee approval, and one consistent unit of account across sites and systems.
• Load every buyer-facing cost in, including HEOR dossiers and the depreciation of placed or loaned equipment that never touches the marketing line.
• Diagnose CAC movement as spend or as win rate. At flat spend, dropping from 40 wins to 25 raises CAC 60 percent on its own.
• Expect payback around 15 months on top of the cycle and protect mid-funnelfunnelThe customer journey from awareness to purchase, typically Awareness, Interest, Consideration, Decision, Action, with prospects narrowing at each stage.View full definition → evidence spend; a half-answered committee is more expensive to win back than to win.